



NIH AIDS Reagent Program
20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: HIV-1 PTE Gag Peptide Pool

Catalog Number: 12437

Lot Number: 260913SASS-1,-2

Provided: 2 vials, lyophilized. Every peptide from the catalog #11554, "HIV-1 PTE Gag Peptides" was used to create two pools. When combined together these pools contain 50 µg of each peptide from cat#11554.

Description: This peptide set is designed to permit expression of the most frequent potential T cell epitopes (PTE) of HIV-1 Gag embedded in the sequences of circulating strains of HIV-1 worldwide. The peptides are 15 a.a. in length and contain naturally occurring 9 a.a. sequences that are potential T cell determinants, captured in an unbiased manner (1).

Purity: >80% purity (HPLC)

Solubility: See attached table. Peptides that are difficult to solubilize can almost always be dissolved in DMSO. Once a peptide is in solution, the DMSO can be slowly diluted with aqueous medium. Care must be taken to ensure that the peptide does not begin to precipitate out of solution.

Please note: Cys and Met containing peptide sequences are highly unstable when stored in DMSO for prolonged periods of time; peptide decay is often observed within days to weeks. If DMSO is required, we recommend freshly-prepared working solutions from freeze dried aliquots of these peptides, and prepared pools.

Special Characteristics: [Click here to view the pooling scheme of these peptides..](#)
[Click here to view the peptides in this complete set.](#)

Please Note: The peptides are listed in the order of decreasing frequency.

Recommended Storage: -20°C

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Contributor: DAIDS, NIAID

References:

1. Li, F., U. Malhotra, P. B. Gilbert, N. R. Hawkins, A. C. Duerr, J. M. McElrath, L. Corey, and S. G. Self. 2006. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. *Vaccine* 24:6893-6904.
2. Malhotra, U., F. Li, J. Nolin, M. Allison, H. Zhao, J. I. Mullins, S. Self, and M. J. McElrath. 2007. Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection. *J Virol* 81:5225-5237.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 PTE Gag Peptide Pool (Cat #12437).

Last Updated: October 09, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.